A comprehensive look at Arvinas ARVN through the lens of 9 analysts within the last quarter:

Gain insights into the future projections for Arvinas by 9 analysts over the next 12 months. The anticipated average price target is $38.44, with a high estimate of $63.00 and a low estimate of $20.00.

Explore a quick overview of how 9 analysts rated Arvinas in the last 3 months. More bullish ratings signify a positive analyst sentiment, while more bearish ratings suggest a negative outlook.

This current average has decreased by 15.39% from the previous average price target of $45.43.

Breaking Down Analyst Ratings: A Detailed Examination

Take a deep dive into the evaluations of financial experts and analysts as we dissect their recent assessments for Arvinas. The Ratings Table below offers an extensive overview of the decisions taken by prominent analysts, their current ratings, and price targets. Offer crucial insights into emerging market trends and investor sentiment by understanding how these experts perceive the company.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Arvinas. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Arvinas compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Arvinas's stock. This examination reveals shifts in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Arvinas's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Arvinas analyst ratings.

All You Need to Know About Arvinas

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Unraveling the Financial Story of Arvinas

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Positive Revenue Trend: Examining Arvinas's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.22% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Arvinas's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -184.97%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -13.9%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Arvinas's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.98%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Arvinas's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: Simplified

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.